Nimodipine - Moligand™, 10mM in DMSO , Gating inhibitor of Ca v1.1;Gating inhibitor of Ca v1.2;Gating inhibitor of Ca v1.3;Gating inhibitor of Ca v1.4;Activator of CFTR;Antagonist of Mineralocorticoid receptor;Allosteric modulator of P2X4, CAS No.66085-59, Gating inhibitor of Ca v1.1;Gating inhibitor of Ca v1.2;Gating inhibitor of Ca v1.3;Gating inhibitor of Ca v1.4;Activator of CFTR;Antagonist of Mineralocorticoid receptor;Allosteric modulator of P2X4

CAS: 66085-59-4 Cat. No.: N408147 Peso molecular: 418.44 Número EC: 266-127-0

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

BAY E 9736 | 1,​4-​dihydro-​2,​6-​dimethyl-​4-​(3-​nitrophenyl)​-3,​5-​pyridinedicarboxylic acid- 3-​(2-​methoxyethyl) 5-​(1-​methylethyl) ester

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Descripción general

Information

Nimodipine Nimodipine (BAY E 9736) is a dihydropyridine calcium channel blocker and an autophagy inhibitor, used in the treatment of high blood pressure.
In vitro

Nimodipine decreases both the peak amplitude and the integrated area of the AHP in an age- and concentration-dependent manner. Nimodipine (100 nM) significantly reduces the AHP in aging CA1 neurons. Nimodipine increases excitability in an age- and concentration-dependent manner by decreasing spike frequency accommodation (increasing the number of action potentials during prolonged depolarizing current injection). Nimodipine decreases accommodation only at higher concentrations in young CA1 neurons. Nimodipine decreases the plateau phase of the calcium AP at concentrations as low as 100 nM in aging neurons and 10 mM in young rat neurons.

In vivo

Nimodipine results in reversible, dose-related suppression of the compound action potential of the auditory nerve (CAP; N1-P1), a prolongation of N1 latency at suprathreshold levels, an elevated CAP threshold, a decrease in N1 latency at a constant amplitude measured at CAP threshold, a reduction in cochlear microphonics (CM), and a reduction of the negative summating potential (SP) to a point where it becomes positive. Nimodipine (10 mg/kg, SC), an L-type dihydropyridine Ca2+ channel antagonist, appears to completely block the establishment of conditioning of cocaine\'s effects, but only partially blocks sensitization to cocaine. Nimodipine (5-20 mg/kg, SC) inhibits in a dose-related manner self-administration both of cocaine and morphine contingent upon a nose-poke response.
Cell Data

cell lines：Karpas 1106P cells

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Sinónimos

BAY E 9736 | 1, ​4-​dihydro-​2, ​6-​dimethyl-​4-​(3-​nitrophenyl)​-3, ​5-​pyridinedicarboxylic acid- 3-​(2-​methoxyethyl) 5-​(1-​methylethyl) ester

Especificaciones y pureza

Moligand™, 10mM in DMSO

Mecanismos bioquímicos y fisiológicos

Nimodipine (BAY E 9736) is a dihydropyridine calcium channel blocker and an autophagy inhibitor, used in the treatment of high blood pressure.

Condiciones de almacenamiento de almacenamiento

Store at -80°C

Enviado en

Dry ice packs + Cold packs

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Grado

Moligand™

Tipo de acción

ACTIVATOR, ALLOSTERIC MODULATOR, ANTAGONIST, GATING INHIBITOR

Mecanismo de acción

Gating inhibitor of Ca v1.1;Gating inhibitor of Ca v1.2;Gating inhibitor of Ca v1.3;Gating inhibitor of Ca v1.4;Activator of CFTR;Antagonist of Mineralocorticoid receptor;Allosteric modulator of P2X4

Nombres e identificadores

• Isómeros SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
• WGK Alemania: 1
• RTECS: US7975500
• Peso molecular: 418.44
• Reaxy-Rn: 459792
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=459792&ln=

Objetivos asociados (humanos)

CYP2C9 Tchem Cytochrome P450 2C9 (1 Activities)

Discover Target: CYP2C9

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

NR3C2 Tclin Mineralocorticoid receptor (1 Activities)

Discover Target: NR3C2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CACNA1C Tclin Voltage-dependent L-type calcium channel subunit alpha-1C (2 Activities)

Discover Target: CACNA1C

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CACNA1F Tchem Voltage-dependent L-type calcium channel subunit alpha-1F (1 Activities)

Discover Target: CACNA1F

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CACNA1S Tclin Voltage-dependent L-type calcium channel subunit alpha-1S (1 Activities)

Discover Target: CACNA1S

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Propiedades químicas y físicas

• Punto de fusión (°C): 125°C

Referencias

1. Bowen Li, Wentao Yu, Lan Yang.  (2023)  Osmundacetone Alleviates Cerebral Ischemia–Reperfusion Injury in Rats.  BIOLOGICAL & PHARMACEUTICAL BULLETIN,  46  (11): (1527-1534).  [PMID:37673653] [10.1248/bpb.b23-00326]

2. Ting Ma, Geng Ou.  (2023)  Fabrication of a highly sensitive electrochemical sensor for the rapid detection of nimodipine.  International Journal of Electrochemical Science,      [PMID:] [10.1016/j.ijoes.2023.01.018]

3. Qiyao Wang, Difan Zhang, Jiani Lu, Jiaying Zhang, Zhenquan Xuan, Luyun Gong, Mengxiang Yang, Lingli Jin, Jingyang Le, An Zhu, Hongze Liang, C. Benjamin Naman, Jinrong Zhang, Li Zhao, Shan He, Qinwen Wang, Hao Liu, Xiaojun Yan, Lingling Zhao, Wei Cui.  (2022)  PLGA-PEG-fucoxanthin nanoparticles protect against ischemic stroke in vivo.  Journal of Functional Foods,      [PMID:] [10.1016/j.jff.2022.105359]

4. Zhu-Jun Zhong, Zhong-Ping Yao, Zi-Qi Shi, Yang-Dan Liu, Li-Fang Liu, Gui-Zhong Xin.  (2021)  Measurement of Intracellular Nitric Oxide with a Quantitative Mass Spectrometry Probe Approach.  ANALYTICAL CHEMISTRY,      [PMID:34107211] [10.1021/acs.analchem.1c01259]

5. Liu Wei, Wang Ruya, Hu Fan, Wu Pinping, Huang Tao, Fizir Meriem, He Hua.  (2018)  Novel mixed hemimicelles based on nonionic surfactant–imidazolium ionic liquid and magnetic halloysite nanotubes as efficient approach for analytical determination.  ANALYTICAL AND BIOANALYTICAL CHEMISTRY,  410  (28): (7357-7371).  [PMID:30294762] [10.1007/s00216-018-1348-4]

6. Nani Wang, Qiaoyan Zhang, Hailiang Xin, Dan Shou, Luping Qin.  (2017)  Osteoblast cell membrane chromatography coupled with liquid chromatography and time-of-flight mass spectrometry for screening specific active components from traditional Chinese medicines.  JOURNAL OF SEPARATION SCIENCE,  40  (22): (4311-4319).  [PMID:28884956] [10.1002/jssc.201700688]

7. Jiale Liu, Kai Liu, Xinyuan Cui, Yujie Ji, Zhaoqi Ding, Zenghui Chang, Junshuo Zhang, Xinyi Wang, Yuanyuan Liu.  (2025)  From gut to brain: donepezil and nimodipine combination therapy improves cognitive deficits in Alzheimer's disease via gut microbiota and metabolites.  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,      [PMID:40737743] [10.1016/j.bbrc.2025.152418]

8. Xingfang Zhang, Liang Gao, Jianv Wang, Wei Zhang, Dong Xu, Yanhua Wang, Tianlong Liu, Kai Gao, Zhen Ren, Yi Ding.  (2025)  Study of the ameliorative effect of β-Bisabolene on ischemic stroke via COX-2 with the Keap1/Nrf2 and MAPK pathways.  EUROPEAN JOURNAL OF PHARMACOLOGY,      [PMID:40441590] [10.1016/j.ejphar.2025.177773]

9. Lang Liu, Jingyu Weng, Lei Yue, Yuanyuan Qin, Jia Yu, Yaqi Li, Shuming Li, Jiaofeng Wu, Yuangui Yang, Zhishu Tang, Hongbo Xu.  (2025)  Rosmarinic acid suppresses ferroptosis and confers neuroprotection in cerebral ischemia-reperfusion via direct KEAP1 inhibition and NRF2 activation.  FREE RADICAL BIOLOGY AND MEDICINE,      [PMID:41167534] [10.1016/j.freeradbiomed.2025.10.291]

10. Lin Tang, Ao Wang, Hecheng Wu, Wenkai Liu, Feng Luo, Jiehua Li, Zhen Li, Hong Tan.  (2025)  Microphase Structure and Component Influence on Drug Sorption: Polyurethane-Drug Interaction Elucidation in Medical Catheter Systems.  ACS Applied Materials & Interfaces,      [PMID:41261068] [10.1021/acsami.5c15217]

11. Xiaofeng Wang, Jue Wang, Xia Zhao, Langui Xie, Rui Yang, Chunmeng Sun, Jiasheng Tu, Huimin Sun.  (2025)  Drug-Dependent Enhancement of Blood–Brain Barrier Permeation by Polysorbate 80 Minor Components.  Pharmaceutics,  17  (12): (1572).  [PMID:41471087] [10.3390/pharmaceutics17121572]

12. Li Anan, Lu Shijie, Shang Xueqing, Zhang He, Xie Min, Lu Qiao, Hu Yongjun.  (2026)  Visualizing xenobiotics and metabolites in zebrafish by VUV-laser desorption post-ionization mass spectrometry imaging.  ANALYTICAL AND BIOANALYTICAL CHEMISTRY,      [PMID:41586896] [10.1007/s00216-026-06344-1]

13. Pongsigeraxi Borjigin, Caixia Deng, Rilaga Su, Juan Li, Ying Ying, Yingsong Chen, Tegexibaiyin Wang.  (2026)  Pearl Powder Fluorescent Carbon Dots Alleviate Neuroinflammation in Cerebral Ischemia/Reperfusion Through Suppression of Anxa2/NF-κB Signaling Pathway.  International Journal of Nanomedicine,      [PMID:] [10.2147/IJN.S567974]